Literature DB >> 35665314

Microorganism Distributions and Antimicrobial Susceptibility in Community-Onset Bacteremia: A 6-Year Longitudinal Multicenter Cohort in Southern Taiwan.

Yi-Tzu Huang1, Chao-Yung Yang2, Chih-Chia Hsieh2, Ming-Yuan Hong2, Ching-Chi Lee3,4.   

Abstract

Background: Prompt administration of appropriate antimicrobials has been correlated with improved prognoses in patients with bacteremia. Because the Clinical and Laboratory Standards Institute (CLSI) has numerously revised the interpretive criteria of susceptibility to numerous antimicrobials, the updated susceptibility is useful for empirical administration.
Methods: In the multicenter retrospective cohort study consisting of adults with community-onset bacteremia in the emergency department (ED) during the period between January 2010 and December 2015, causative microorganisms were identified by the Vitek 2 system and prospectively collected. Antimicrobial susceptibility were respectively tested by the disk diffusion method for aerobes and the agar dilution method for anaerobes, in accordance with the contemporary CLSI criteria. Clinical information was retrospectively retrieved by reviewing the medical records.
Results: Of the total 3,194 patients and 3,583 causative microorganisms, the leading source of bacteremia was the urinary tract infection (1,034 patients, 32.4%), and Escherichia coli accounted for the majority (1,332 isolates, 37.2%) of the total microorganisms. Overall, the lowest (58.2%) and highest (93.5%) susceptibility to cefazolin and piperacillin/tazobactam were, respectively, observed. In the leading five sources of bacteremia, in terms of the urinary tract infections, pneumonia, intraabdominal infections, skin and soft-tissue infections, and biliary tract infections, cefazolin or cefuroxime was only active against 49.3%-62.3% or 63.2%-74.1% of causative microorganisms, respectively. Notably, E. coli , Klebsiella species, and Proteus mirabilis (EKP) with the production of extended-spectrum beta-lactamases (ESBLs) accounted for 7.4% (142 isolates) of 1,908 EKP and 4.0% of all 3,583 microorganisms; and methicillin-resistant Staphylococcus aureus (MRSA) accounted for 37.7% (158 isolates) of S . aureus and 4.4% of all causative isolates. Conclusions: For adults with community-onset bacteremia, a low incidence (approximate 4%) of ESBL-producing EKP and MRSA among all causative microorganisms, but low susceptibility to cefazolin and cefuroxime were recognized. To achieve favorable prognoses by prompt administration of appropriate antimicrobials in EDs, our findings might offer useful information for the antimicrobial stewardship program.

Entities:  

Keywords:  antibiotic therapy ; bacteremia ; community ; empirical ; susceptibility

Year:  2022        PMID: 35665314      PMCID: PMC9126826          DOI: 10.6705/j.jacme.202203_12(1).0001

Source DB:  PubMed          Journal:  J Acute Med        ISSN: 2211-5587


  28 in total

1.  Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance.

Authors:  Melissa Viray; Darren Linkin; Joel N Maslow; Donald D Stieritz; Lesley S Carson; Warren B Bilker; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2005-01       Impact factor: 3.254

2.  Prognosis and prognostic research: Developing a prognostic model.

Authors:  Patrick Royston; Karel G M Moons; Douglas G Altman; Yvonne Vergouwe
Journal:  BMJ       Date:  2009-03-31

3.  Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections.

Authors:  N Deborah Friedman; Keith S Kaye; Jason E Stout; Sarah A McGarry; Sharon L Trivette; Jane P Briggs; Wanda Lamm; Connie Clark; Jennifer MacFarquhar; Aaron L Walton; L Barth Reller; Daniel J Sexton
Journal:  Ann Intern Med       Date:  2002-11-19       Impact factor: 25.391

Review 4.  Population-based epidemiology and microbiology of community-onset bloodstream infections.

Authors:  Kevin B Laupland; Deirdre L Church
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

5.  Propensity score-matched analysis comparing the therapeutic efficacies of cefazolin and extended-spectrum cephalosporins as appropriate empirical therapy in adults with community-onset Escherichia coli, Klebsiella spp. and Proteus mirabilis bacteraemia.

Authors:  Chih-Chia Hsieh; Chung-Hsun Lee; Ming-Yuan Hong; Yuan-Pin Hung; Nan-Yao Lee; Wen-Chien Ko; Ching-Chi Lee
Journal:  Int J Antimicrob Agents       Date:  2016-10-26       Impact factor: 5.283

6.  Burden of community-onset bloodstream infection: a population-based assessment.

Authors:  K B Laupland; D B Gregson; W W Flemons; D Hawkins; T Ross; D L Church
Journal:  Epidemiol Infect       Date:  2006-12-07       Impact factor: 2.451

7.  The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000.

Authors:  Tsai-Ling Lauderdale; L Clifford McDonald; Yih-Ru Shiau; Pei-Chen Chen; Hui-Ying Wang; Jui-Fen Lai; Monto Ho
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803

8.  Empirical third-generation cephalosporin therapy for adults with community-onset Enterobacteriaceae bacteraemia: Impact of revised CLSI breakpoints.

Authors:  Chih-Chia Hsieh; Chung-Hsun Lee; Ming-Chi Li; Ming-Yuan Hong; Chih-Hsien Chi; Ching-Chi Lee
Journal:  Int J Antimicrob Agents       Date:  2016-02-23       Impact factor: 5.283

9.  Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors.

Authors:  Cassandra D Salgado; Barry M Farr; David P Calfee
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

10.  The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis.

Authors:  Wu-Pu Lin; Jann-Tay Wang; Shan-Chwen Chang; Feng-Yee Chang; Chang-Phone Fung; Yin-Ching Chuang; Yao-Shen Chen; Yih-Ru Shiau; Mei-Chen Tan; Hui-Ying Wang; Jui-Fen Lai; I-Wen Huang; Tsai-Ling Lauderdale
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.